Qualitative detection of the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible. V617F testing may be ordered separately, concurrently with full exon 12-13 sequencing, with reflex to exon 12-13 sequencing, or as part of the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL. Testing is approved for specimens from the state of New York.
The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately 40% of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Mutation analysis helps differentiate reactive conditions from myeloproliferative neoplasms (MPNs).
- Peripheral Blood: 5 mL EDTA tube
- Bone Marrow: 2 mL EDTA tube
Note: Test is RNA-based. Please select Extract & Hold – RNA if specimen hold service is desired. If considering the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL test as an add-on, we recommend adding Extract & Hold – DNA with Extract & Hold – RNA order.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.
7 days